Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 12/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.58 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.58 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluconazole SCHEMBL5503188 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL5597261 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL3151 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27971366 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL20305060 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL28141272 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27534402 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27971503 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL2244102 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27514614 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1079 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144861-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | BioNTech SE (DE) | 2026-05-28 | — | — | US | claimed |
| CN-121579164-A | Task allocation method and device of multi-core processor and vehicle | 深蓝汽车科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4694857-A1 | VACCINE MIXING METHOD, SYRINGE AND SYSTEM | BioNTech SE (DE) | 2026-02-18 | — | — | EP | claimed |
| US-20260008854-A1 | METHODS FOR VACCINATION OF A SUBJECT TREATED WITH AN FCRN ANTAGONIST | argenx BV (BE) | 2026-01-08 | — | — | US | claimed |
| WO-2025233685-A1 | INTRAVENOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF | argenx BV (BE) | 2025-11-13 | — | — | WO | claimed |
| US-20250312440-A1 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2025-10-09 | — | — | US | claimed |
| EP-4604995-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | BioNTech SE (DE) | 2025-08-27 | — | — | EP | claimed |
| US-20250195631-A1 | ANTIGEN DELIVERING SALMONELLA FOR USE AS A TUMOR HOMING BEACON TO REFOCUS PREEXISTING, VACCINE GENERATED T CELLS TO COMBAT CANCER | UNIVERSITY OF MASSACHUSETTS | 2025-06-19 | — | — | US | claimed |
| WO-2025120580-A1 | COMPOSITIONS AND METHODS FOR INITIATING A MUCOSAL IMMUNE RESPONSE | IX BIOPHARMA LTD (SG) | 2025-06-12 | — | — | WO | claimed |
| WO-2025097022-A1 | MULTICOMPONENT SYSTEMS FOR SITE-SPECIFIC GENOME MODIFICATIONS | ADDITION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | claimed |
| CN-114528368-B | Spatial relation extraction method based on fusion of pre-training language model and text features | 南京师范大学 | 2023-08-25 | — | — | CN | claimed |
| CN-116165881-A | Design method of steering law with variable configuration roll angle and unavoidable singular | 北方民族大学 | 2023-05-26 | — | — | CN | claimed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | claimed |
| CN-115551352-A | Active compound combinations and fungicide compositions comprising them | 拜耳公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115361708-A | 5G-based electricity consumption data detection technology | 中国移动通信集团广东有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-110689508-B | Sparse structure manifold embedding-based IHS remote sensing image fusion method | 西安理工大学 | 2022-07-01 | — | — | CN | claimed |
| CN-107787630-B | Device for influencing the position of an agricultural attachment | 迪尔公司 | 2022-06-03 | — | — | CN | claimed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | claimed |
| US-11305005-B2 | Methods of use of influenza vaccine for prevention of pneumonia | SANOFI PASTEUR INC. (US) | 2022-04-19 | — | — | US | claimed |
| CN-113987443-A | Multi-cloud and multi-chain collaborative electronic medical data security sharing method | 西安邮电大学 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144861-A1 | COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION | CD4, LGALS3BP, SARNP | CYP3A4 4114/4885CYP2C9 4008/4885CYP2C19 4051/4885 |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | TAS2R42, TAS2R39, TAS2R45 | CYP3A4 1879/4885CYP2C9 850/4885CYP2C19 416/4885 |
| US-20260008854-A1 | METHODS FOR VACCINATION OF A SUBJECT TREATED WITH AN FCRN ANTAGONIST | FCGRT, FCGR3B, FCGR1A | CYP3A4 1781/4885CYP2C9 1991/4885CYP2C19 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.